OSE Immunotherapeutics Corrects Voting Rights Error Before General Meeting

OSE Immunotherapeutics has corrected a material error related to the total number of voting rights and shares comprising its share capital. An error was identified during preparations for the General Meeting on September 30, 2025, regarding the acceleration of the vesting period for 546,919 free shares. This adjustment had no impact on beneficiary rights or previous votes and was urgently addressed by the Board on September 23.

The company's share capital comprises 22,463,262 shares with 27,859,524 theoretical voting rights. Despite accusations from a minority shareholder group alleging "fraudulent manipulation," OSE maintains the error was unintentional, arising from a legal misqualification by a corporate advisor.

Furthermore, OSE has noted an amended shareholder agreement. The Shareholder Group, holding about 14.22% of share capital and 19.05% of voting rights, supports resolutions proposed by the Board concerning its composition. Proxy advisory firms have favorably recommended specific board resolutions.